Albert Nguyen

Albert Nguyen serves as a Contract Specialist responsible for managing the full lifecycle of complex scientific and technical acquisitions, ensuring compliance with federal procurement regulations and mission-aligned outcomes. He plays a critical role in translating agency research objectives into executable contract vehicles, primarily supporting R&D initiatives in life sciences and engineering disciplines. His acquisitions typically involve competitive sealed bidding and negotiated procurements under FAR Part 15, with a strong emphasis on performance-based requirements and technical evaluation criteria. Albert ensures that contract terms align with scientific deliverables, intellectual property protections, and data rights clauses specific to federally funded research. While no specific contractor relationships are currently identifiable due to data limitations, Albert engages with a diverse range of vendors including academic research institutions, private-sector biotechnology firms, and specialized engineering service providers. His procurement approach emphasizes technical capability over price alone, fostering long-term partnerships with contractors demonstrating proven expertise in experimental design, laboratory operations, and translational research. He consistently prioritizes proposals with clear methodologies, qualified personnel, and robust quality assurance plans. Albert’s contracting portfolio is entirely non-set-aside, with 100% of awards issued under full and open competition. This reflects a strategic focus on accessing the broadest possible pool of technical expertise rather than socioeconomic preferences. While he does not routinely utilize 8(a), HUBZone, or SDVOSB set-asides, his process remains fully compliant with small business participation goals through subcontracting opportunities and mentor-protégé arrangements when contractually appropriate. His primary procurement focus lies in NAICS 541714 (Biotechnology R&D) and 541715 (Physical, Engineering, and Life Sciences R&D), where he procures services such as preclinical testing, molecular analysis, clinical trial support, and laboratory instrumentation development. Albert brings deep familiarity with regulatory frameworks governing biomedical research, including FDA alignment, GLP/GCP standards, and institutional review board compliance, positioning him as a key facilitator of innovation in the federal science and technology ecosystem.